EP
Highly rated in
22
conditions

Dr. Edward L. Pan

University Hospital Medical Oncology Clinic
Dallas, TX
Highly rated in
22
conditions
Specialties:Neurology
Experience:27 Years
Clinical Trials:Currently Recruiting for 6 Trials
Accepts:New Patients
Highly rated in
22
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Edward L. Pan's experience treating your condition:
About Dr. Edward L. Pan

Edward Pan is a Neurologist in Dallas, Texas. Pan has been practicing medicine for over 27 years and is highly rated in 22 conditions, according to our data. His top areas of expertise are Astrocytoma, Glioma, Glioblastoma, and Brain Tumor. He is licensed to treat patients in Florida and Texas. Pan is currently accepting new patients.

His clinical research consists of co-authoring 53 peer reviewed articles and participating in 17 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Edward L. Pan it is best to call his office and ask if your insurance is accepted.

Dr. Edward L. Pan accepts the following insurance:

  •  Ambetter
Call to see if your plan is accepted.
Locations
2201 Inwood Rd, 3rd Floor, Suite 500, Dallas, TX 75390
Background & Education
Graduate Institution
Boston University School Of Medicine, 1996
Specialties
Neurology
Licenses
Psychiatry & Neurology in FL
Hospital Affiliations
William P Clements Jr University Hospital
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials
A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination With Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma
Enrollment Status: Recruiting
Publish Date: November 16, 2022
Intervention Type: Biological, Radiation
Study Drugs: IpilimumabNivolumab
Study Phase: Phase 1/Phase 2
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Enrollment Status: Recruiting
Publish Date: March 24, 2022
Intervention Type: Drug, Radiation
Study Drugs: Concomitant Temozolomide (TMZ)ProcarbazineAdjuvant Temozolomide (TMZ)CCNUVincristine
Study Phase: Phase 3
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
Enrollment Status: Recruiting
Publish Date: December 08, 2022
Intervention Type: Drug, Radiation
Study Drugs: TemozolomideLomustineRegorafenibPaxalisibVAL-083
Study Phase: Phase 2/Phase 3
Genomically-Guided Treatment Trial in Brain Metastases
Enrollment Status: Recruiting
Publish Date: June 07, 2022
Intervention Type: Drug
Study Drugs: AbemaciclibPaxalisibEntrectinib
Study Phase: Phase 2
Maintenance Obinutuzumab for Primary Central Nervous System Lymphoma Complete or Partial Responders
Enrollment Status: Recruiting
Publish Date: June 13, 2022
Intervention Type: Other, Biological, Procedure
Study Drug: Obinutuzumab
Study Phase: Phase 2
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Enrollment Status: Recruiting
Publish Date: September 27, 2022
Intervention Type: Drug
Study Drugs: VismodegibGSK2256098CapivasertibAbemaciclib
Study Phase: Phase 2
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: August 13, 2018
Intervention Type: Biological
Study Phase: Phase 3
A Phase 1/2 Multi-Center, Safety and Efficacy Study Evaluating Intravenously Administered 131I-TM601 in Patients With Progressive and/or Recurrent Malignant Glioma
Enrollment Status: Unknown status
Publish Date: July 17, 2009
Intervention Type: Drug
Study Drug: 131I-TM601
Study Phase: Phase 1/Phase 2
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
Phase I Study of Bendamustine With Concurrent Whole Brain Radiation Therapy in Patients With Brain Metastases From Solid Tumors
Enrollment Status: Terminated
Publish Date: December 18, 2012
Intervention Type: Drug
Study Phase: Phase 1
Phase I/II Study of R04929097 With Bevacizumab in Patients With Recurrent Malignant Glioma
Enrollment Status: Terminated
Publish Date: December 14, 2015
Intervention Type: Drug, Other, Biological
Study Phase: Phase 1/Phase 2
A Single Arm Pilot Study of Intrathecally Administered DepoCyt® With Systemic Sorafenib in the Treatment of Neoplastic Meningitis From Solid Tumors
Enrollment Status: Terminated
Publish Date: September 09, 2013
Intervention Type: Drug
Study Phase: Not Applicable
Pilot Study of Abemaciclib With Bevacizumab in Recurrent Glioblastoma Patients With Loss of CDKN2A/B or Gain or Amplification of CDK4/6
Enrollment Status: Active, not recruiting
Publish Date: January 25, 2022
Intervention Type: Drug
Study Drugs: AbemaciclibBevacizumab
Study Phase: Early Phase 1
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: October 23, 2018
Intervention Type: Drug
Study Phase: Phase 3
A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma Multiforme
Enrollment Status: Completed
Publish Date: November 19, 2012
Intervention Type: Drug
Study Phase: Phase 2
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active, not recruiting
Publish Date: July 28, 2022
Intervention Type: Other, Drug
Study Drugs: TemozolomideVeliparib
Study Phase: Phase 2/Phase 3
A Phase II Study of Irinotecan HCI in Patients With Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas
Enrollment Status: Terminated
Publish Date: March 23, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 11 Less Clinical Trials -
53 Total Publications
Primary central nervous system lymphoma: a real-world comparison of therapy access and outcomes by hospital setting.
Journal: Neuro-oncology practice
Published: May 23, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
BM
Dr. Berge A. Minassian
Neurology | Child Neurology | Pediatrics
Highly rated in
22
conditions
Neurology
Child Neurology
Pediatrics

Childrens Health

Childrens Medical Center Dallas

1935 Medical District Dr, 
Dallas, TX 
 0.8 mi

Berge Minassian is a Neurologist and a Child Neurologist in Dallas, Texas. Minassian has been practicing medicine for over 31 years and is highly rated in 22 conditions, according to our data. His top areas of expertise are Dentatorubral-Pallidoluysian Atrophy, Lafora Disease, Adult Polyglucosan Body Disease, and Epilepsy with Myoclonic-Atonic Seizures. He is licensed to treat patients in Texas. Minassian is currently accepting new patients.

RS
Dr. Raphael Schiffmann
Neurology | Neurosurgery
Highly rated in
11
conditions
Neurology
Neurosurgery

Baylor Scott & White Health

Baylor University Medical Center

3500 Gaston Ave, 
Dallas, TX 
 4.1 mi

Raphael Schiffmann is a Neurologist and a Neurosurgery expert in Dallas, Texas. Schiffmann has been practicing medicine for over 43 years and is highly rated in 11 conditions, according to our data. His top areas of expertise are Fabry Disease, Gaucher Disease Type 3, Leukodystrophy, and Gaucher Disease. He is licensed to treat patients in Texas. Schiffmann is currently accepting new patients.

BG
Dr. Benjamin M. Greenberg
Neurology
Highly rated in
14
conditions
Neurology

University of Texas Southwestern Medical Center

The Multiple Sclerosis And Neuroimmunology Clinic At James W. Aston Ambulatory Care Center

5303 Harry Hines Blvd, 
Dallas, TX 
 0.6 mi

Benjamin Greenberg is a Neurologist in Dallas, Texas. Greenberg has been practicing medicine for over 22 years and is highly rated in 14 conditions, according to our data. His top areas of expertise are Optic Neuritis, Multiple Sclerosis (MS), Neuromyelitis Optica, and Transverse Myelitis. He is licensed to treat patients in Maryland and Texas. Greenberg is currently accepting new patients.